Statins in cardiovascular prevention in the oldest-old. A black hole

I. Liguori, L. Aran, G. Bulli, G. Russo, F. Curcio, G. Sasso, F. Pirozzi, David Della Morte, G. Gargiulo, G. Testa, F. Cacciatore, D. Bonaduce, Pasquale Abete

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVDs) and cardiovascular (CV) mortality. The evaluation of total CV risk is necessary for prevention of CV events, but the most used assessment tools do not include the elderly population. Among CV risk factors, hypercholesterol-emia increases with the age, but the results about the association between total cholesterol (TC) levels and mortality in the elderly population are controversial. Statins are the first-choice drug for lipid-lowering therapy in the elderly due to their efficacy and safety. In primary prevention there are no recommendations to the use of statins in older adults because they do not reduce the risk of CV and all-cause mortality. On the contrary, statin treatment is recommend both in older than in younger people in secondary prevention because of the reduction of CV and all-causes mortality. High-intensity statins are more effective in the elderly population, but these dosages are associated to an increased incidence of adverse reactions, especially liver dysfunction. Finally, the degree of clinical frailty is inversely related to total cholesterol in the elderly and, accordingly, lower cholesterol levels are associated to higher mortality in this population. There are no studies that specifically evaluated the benefit of lipid-lowering therapy in severely frail older adults and a narrative-based approach, instead of an evidence-based one, has been used to choose the better treatment plan.

Original languageEnglish (US)
Pages (from-to)263-270
Number of pages8
JournalJournal of Gerontology and Geriatrics
Volume65
Issue number4
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Population
Cholesterol
Lipids
Frail Elderly
Incidence
Primary Prevention
Therapeutics
Secondary Prevention
Liver Diseases
Cardiovascular Diseases
Safety
Pharmaceutical Preparations

Keywords

  • Cardiovascular risk
  • Cholesterol
  • Elderly
  • Statins

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Liguori, I., Aran, L., Bulli, G., Russo, G., Curcio, F., Sasso, G., ... Abete, P. (2017). Statins in cardiovascular prevention in the oldest-old. A black hole. Journal of Gerontology and Geriatrics, 65(4), 263-270.

Statins in cardiovascular prevention in the oldest-old. A black hole. / Liguori, I.; Aran, L.; Bulli, G.; Russo, G.; Curcio, F.; Sasso, G.; Pirozzi, F.; Della Morte, David; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; Abete, Pasquale.

In: Journal of Gerontology and Geriatrics, Vol. 65, No. 4, 01.01.2017, p. 263-270.

Research output: Contribution to journalReview article

Liguori, I, Aran, L, Bulli, G, Russo, G, Curcio, F, Sasso, G, Pirozzi, F, Della Morte, D, Gargiulo, G, Testa, G, Cacciatore, F, Bonaduce, D & Abete, P 2017, 'Statins in cardiovascular prevention in the oldest-old. A black hole', Journal of Gerontology and Geriatrics, vol. 65, no. 4, pp. 263-270.
Liguori I, Aran L, Bulli G, Russo G, Curcio F, Sasso G et al. Statins in cardiovascular prevention in the oldest-old. A black hole. Journal of Gerontology and Geriatrics. 2017 Jan 1;65(4):263-270.
Liguori, I. ; Aran, L. ; Bulli, G. ; Russo, G. ; Curcio, F. ; Sasso, G. ; Pirozzi, F. ; Della Morte, David ; Gargiulo, G. ; Testa, G. ; Cacciatore, F. ; Bonaduce, D. ; Abete, Pasquale. / Statins in cardiovascular prevention in the oldest-old. A black hole. In: Journal of Gerontology and Geriatrics. 2017 ; Vol. 65, No. 4. pp. 263-270.
@article{1e93cebaf9a04c059f81881ceb75767f,
title = "Statins in cardiovascular prevention in the oldest-old. A black hole",
abstract = "Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVDs) and cardiovascular (CV) mortality. The evaluation of total CV risk is necessary for prevention of CV events, but the most used assessment tools do not include the elderly population. Among CV risk factors, hypercholesterol-emia increases with the age, but the results about the association between total cholesterol (TC) levels and mortality in the elderly population are controversial. Statins are the first-choice drug for lipid-lowering therapy in the elderly due to their efficacy and safety. In primary prevention there are no recommendations to the use of statins in older adults because they do not reduce the risk of CV and all-cause mortality. On the contrary, statin treatment is recommend both in older than in younger people in secondary prevention because of the reduction of CV and all-causes mortality. High-intensity statins are more effective in the elderly population, but these dosages are associated to an increased incidence of adverse reactions, especially liver dysfunction. Finally, the degree of clinical frailty is inversely related to total cholesterol in the elderly and, accordingly, lower cholesterol levels are associated to higher mortality in this population. There are no studies that specifically evaluated the benefit of lipid-lowering therapy in severely frail older adults and a narrative-based approach, instead of an evidence-based one, has been used to choose the better treatment plan.",
keywords = "Cardiovascular risk, Cholesterol, Elderly, Statins",
author = "I. Liguori and L. Aran and G. Bulli and G. Russo and F. Curcio and G. Sasso and F. Pirozzi and {Della Morte}, David and G. Gargiulo and G. Testa and F. Cacciatore and D. Bonaduce and Pasquale Abete",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "263--270",
journal = "Journal of Gerontology and Geriatrics",
issn = "2499-6564",
publisher = "Pacini Editore s.r.l.",
number = "4",

}

TY - JOUR

T1 - Statins in cardiovascular prevention in the oldest-old. A black hole

AU - Liguori, I.

AU - Aran, L.

AU - Bulli, G.

AU - Russo, G.

AU - Curcio, F.

AU - Sasso, G.

AU - Pirozzi, F.

AU - Della Morte, David

AU - Gargiulo, G.

AU - Testa, G.

AU - Cacciatore, F.

AU - Bonaduce, D.

AU - Abete, Pasquale

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVDs) and cardiovascular (CV) mortality. The evaluation of total CV risk is necessary for prevention of CV events, but the most used assessment tools do not include the elderly population. Among CV risk factors, hypercholesterol-emia increases with the age, but the results about the association between total cholesterol (TC) levels and mortality in the elderly population are controversial. Statins are the first-choice drug for lipid-lowering therapy in the elderly due to their efficacy and safety. In primary prevention there are no recommendations to the use of statins in older adults because they do not reduce the risk of CV and all-cause mortality. On the contrary, statin treatment is recommend both in older than in younger people in secondary prevention because of the reduction of CV and all-causes mortality. High-intensity statins are more effective in the elderly population, but these dosages are associated to an increased incidence of adverse reactions, especially liver dysfunction. Finally, the degree of clinical frailty is inversely related to total cholesterol in the elderly and, accordingly, lower cholesterol levels are associated to higher mortality in this population. There are no studies that specifically evaluated the benefit of lipid-lowering therapy in severely frail older adults and a narrative-based approach, instead of an evidence-based one, has been used to choose the better treatment plan.

AB - Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVDs) and cardiovascular (CV) mortality. The evaluation of total CV risk is necessary for prevention of CV events, but the most used assessment tools do not include the elderly population. Among CV risk factors, hypercholesterol-emia increases with the age, but the results about the association between total cholesterol (TC) levels and mortality in the elderly population are controversial. Statins are the first-choice drug for lipid-lowering therapy in the elderly due to their efficacy and safety. In primary prevention there are no recommendations to the use of statins in older adults because they do not reduce the risk of CV and all-cause mortality. On the contrary, statin treatment is recommend both in older than in younger people in secondary prevention because of the reduction of CV and all-causes mortality. High-intensity statins are more effective in the elderly population, but these dosages are associated to an increased incidence of adverse reactions, especially liver dysfunction. Finally, the degree of clinical frailty is inversely related to total cholesterol in the elderly and, accordingly, lower cholesterol levels are associated to higher mortality in this population. There are no studies that specifically evaluated the benefit of lipid-lowering therapy in severely frail older adults and a narrative-based approach, instead of an evidence-based one, has been used to choose the better treatment plan.

KW - Cardiovascular risk

KW - Cholesterol

KW - Elderly

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85039803759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039803759&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85039803759

VL - 65

SP - 263

EP - 270

JO - Journal of Gerontology and Geriatrics

JF - Journal of Gerontology and Geriatrics

SN - 2499-6564

IS - 4

ER -